X @Bloomberg
Bloomberg·2025-11-06 01:15

Company Overview - Evommune, a biotechnology company, focuses on chronic inflammatory diseases [1] Financial Highlights - Evommune raised $150 million in an initial public offering (IPO) [1]

X @Bloomberg - Reportify